Intu Diagnostics
Intu Diagnostics develops a lab-independent molecular diagnostics platform, initially focused on HPV testing in women's health.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Intu Diagnostics, Thalia Therapeutics, RarEarth — lab-free testing, clinical RNA and European rare earths — Daily News June 26, 2026
Listen to the episodeAbout Intu Diagnostics
Intu Diagnostics is a Leipzig-based healthtech startup spun out of the Fraunhofer Institute for Cell Therapy and Immunology. The company is developing a lab-free molecular diagnostics platform designed to bring reliable testing outside centralised laboratories and into homes, clinics and low-infrastructure settings. Its €1.1M bridge round will support IP, pilot manufacturing and preparation for scale-up.
The Story
The technology comes from Fraunhofer research; Intu Diagnostics was incorporated in March 2023 by Skaiste Arbaciauskaite and Dirk Kuhlmeier.
How Intu Diagnostics works
Business Model
B2B/B2G diagnostics platform with potential distribution through healthcare systems, clinics, diagnostics partners and public health programmes.
Revenue Model
Not disclosed; likely sale/licensing of tests, cartridges, diagnostic kits and healthcare partnerships.
Products & Services
Key Products
- Lab-free molecular diagnostics platform
- HPV testing platform
Core Use Cases
- HPV testing
- Cervical cancer screening
- Infectious disease diagnostics
- Low-resource molecular testing
Market & Clients
Key Customers
Healthcare systems, clinics, screening programmes, diagnostics partners and potential at-home users.
Geographic Presence
How Intu Diagnostics competes
Competitors
Competitive Advantages
- No laboratory infrastructure required
- No specialised equipment dependency
- Fraunhofer research background
- Platform adaptability across infectious diseases
How Intu Diagnostics grows
Growth Strategy
Strengthen IP, pilot manufacturing and validation before seed financing and scale-up.
Distribution Model
Partnership con sistemi sanitari, programmi di screening, cliniche e potenziali distributor diagnostics.
Moat (Defensibility)
Core technology, patents, Fraunhofer research base and potential regulatory/clinical validation.
Regulatory Context
Medical diagnostics subject to EU and national regulatory requirements.
Key Risks
- Regulatory approval
- Clinical validation
- Manufacturing scale-up
- Adoption in healthcare workflows
Strategic Insights
- Distributed diagnostics is a form of healthcare infrastructure.
- Public research spin-offs can create high-impact products if they move from technical validation to production.
- An HPV first use case can open a broader infectious disease testing platform.
Funding & Investors
Total Funding
Funding Rounds
- 2026 - Strategic bridge round: €1.1M
Key Investors
Founding Team
Founders
Key Executives
- Skaiste Arbaciauskaite - Co-founder
- Dirk Kuhlmeier - Co-founder
Key Metrics
Lessons from Intu Diagnostics
- Technology transfer requires intermediate milestones: IP, pilot manufacturing, validation and seed readiness.
- In diagnostics, value is not only accuracy but operational accessibility.
- Starting from a concrete clinical use case makes a broader platform legible.
Similar Startups
INVITRIS
Biotechnology company focused on advancing research and development in life sciences and medical technology.
Read AnalysisZedira
Specialised supplier of transglutaminase-related research products and services, catalysing academic and industrial R&D across food science, pharma, and biotech.
Read AnalysisPrimogene
Primogene produces complex biomolecules through sustainable enzymatic processes for nutrition, personal care and pharmaceutical raw materials.
Read Analysis